Here’s what you should know:
1. WeissLaw, which is following standard practice after a large acquisition is announced, is attempting to file a class action suit against Envision on behalf of its stockholders.
2. The legal firm has a two-pronged argument:
An analyst set a target acquisition price of $51 per share
Envision traded at $57.40 in August 2017
3. Despite the contrarian analyst, the majority of market analysts predicted a deal in the high $40 per share range. KKR is acquiring Envision for $46 per share.
4. Envision’s board also said on record they’d accept a bid in the high $40 per share range.
More articles on improving performance:
Ophthalmology ASC acquisitions exploded in 2017: 4 key transactions in the Northeast
7 things for ASC leaders to know for Thursday — June 14, 2018
Johnson & Johnson, Aetna CEOs land among the 46 top-earning execs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
